The Manila Times

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common ...

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity ...
Infectious Disease Advisor

Higher Clinical Cure Rates With Ceftolozane-Tazobactam in MDR, DTR P aeruginosa

Ceftolozane-tazobactam shows a higher clinical cure rate than ceftazidime-avibactam for MDR/DTR P aeruginosa infections.
The BMJ

When I use a word . . . The earliest placebo

An antedating, lexicographically speaking, is an earlier instance of the use of a word in a text than had previously been ...

H. Lundbeck A/S: Lundbeck to showcase new neurology data at the American Academy of ...

Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy (MSA), highlighting Lundbeck's biology-driven approach to developing treatments for serious ...

F. Hoffmann-La Roche Ltd: FDA accepts application for Roche's Gazyva/Gazyvaro for the ...

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If app ...